584 results match your criteria: "Germany W.L.; and Radiology Center Mannheim[Affiliation]"
Evaluating Mitral TEER in the Management of Moderate Secondary Mitral Regurgitation Among Heart Failure Patients.
JACC Heart Fail
August 2024
Ascension Saint Thomas, Nashville, Tennessee, USA.
Background: Moderate secondary mitral regurgitation (SMR) represents a subgroup of heart failure (HF) patients with treatment restricted to medical therapy. Outcomes in patients with moderate SMR treated with mitral transcatheter edge-to-edge repair (M-TEER) are less well known.
Objectives: The aim of this study was to assess the safety and effectiveness of M-TEER in subjects with moderate SMR using the EXPANDed studies.
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
N Engl J Med
October 2024
From the Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) - both in the United Kingdom; National Heart Centre Singapore and Duke-National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST "Spedali Civili" Hospital, Brescia (S.N.) - all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) - all in the Netherlands; Université de Lorraine, INSERM Clinical Investigation Centre, Centre Hospitalier Universitaire, Nancy, France (F.Z.); University of Malaya, Kuala Lumpur, Malaysia (I.Z.A.); Centro de Estudios Clínicos de Querétaro, Santiago de Querétaro (M.A.A.-G.), and Hospital Cardiologico Aguascalientes, Aguascalientes (G.L.-E.) - both in Mexico; Cardiology Research Department, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, Australia (J.J.A.); the Department of Cardiology and Angiology, Hannover Medical School, Hannover (J.B.), and Bayer, Wuppertal (P.K.) - both in Germany; Beijing Anzhen Hospital, Capital Medical University, Beijing (M.C.-S.); General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital, and National Yang Ming Chiao Tung University, Taipei, Taiwan (C.-E.C.); Emergency Institute for Cardiovascular Diseases "Prof. Dr. C.C. Iliescu," University of Medicine Carol Davila, Bucharest, Romania (O.C.); Clinical Cardiology, Heart Failure and Research, Max Super Specialty Hospital, New Delhi, India (V.C.); the Department of Cardiology, Bellvitge University Hospital, and Bellvitge Biomedical Research Institute, Centro de Investigación Biomédica En Red Enfermedades Cardiovasculares, University of Barcelona, L'Hospitalet de Llobregat, Barcelona (J.C.-C.); the Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens (G.F.); the Department of Internal Medicine, Hospital São Francisco Xavier, and NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal (C.F.); the Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College, Krakow, Poland (G.G.); the Heart Institute, Kaplan Medical Center, Rehovot, and Hebrew University, Jerusalem - both in Israel (S.G.); the Faculty of Medicine, Comenius University, Bratislava, Slovakia (E.G.); the Division of Cardiology, Severance Hospital, and Yonsei University Health System, Seoul, South Korea (S.K.); the Department of Noninvasive Cardiology, National Cardiology Hospital, Sofia, Bulgaria (T.K.); St. Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City (M.N.K.); Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia (G.L.); Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Hong Kong (A.P.-W.L.); University Clinic of Lomonosov Moscow State University, Moscow (V. Mareev); Universidad Nacional de Córdoba, Córdoba, Argentina (F.A.M.); the Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (V. Melenovský); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Centro Cardiovascular Colombiano, Clínica Santa María, Medellin, Colombia (C.I.S.); Cardiovascular Division, Instituto de Pesquisa Clínica de Campinas, Campinas (J.F.K.S.), and Bayer, São Paulo (F.A.) - both in Brazil; Kawaguchi Cardiovascular and Respiratory Hospital, Saitama, Japan (N.S.); the Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark (M. Schou); the Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore (K.S.); Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand (R.T.); Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital (J.A.U.), University of Toronto (J.A.U., S.V.), and the Division of Cardiac Surgery, St. Michael's Hospital (S.V.), Toronto, and the Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg (S.Z.) - both in Canada; Heart Centre, Turku University Hospital, Turku, Finland (H.U.); the Department of Medicine, University of Minnesota, and Minneapolis VA Health Care System, Minneapolis (O.V.); the Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria (D.L.); National Scientific Center, Strazhesko Institute of Cardiology, National Academy of Medical Sciences, Kyiv, Ukraine (L.V.); Dokuz Eylul University Medical Faculty, Cardiology Department, Izmir, Turkey (M.B.Y.); and Bayer, Whippany, NJ (P.V.).
Article Synopsis
- Steroidal mineralocorticoid receptor antagonists help patients with heart failure and reduced ejection fraction, but their effectiveness in those with mildly reduced or preserved ejection fraction is unclear, indicating a need for further research on finerenone.
- In a double-blind study, patients with heart failure (ejection fraction 40% or greater) were assigned to receive either finerenone or a placebo to assess its impact on heart failure events and cardiovascular death.
- Results showed that finerenone led to fewer worsening heart failure events and a lower overall rate of primary outcome events compared to placebo, although it also carried a higher risk of hyperkalemia.
Impact of Renal and Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair.
J Am Coll Cardiol
December 2024
Mount Sinai, New York, New York, USA.
Article Synopsis
- The TRILUMINATE Pivotal trial investigated the impact of tricuspid regurgitation (TR) on end-organ function and the effectiveness of transcatheter edge-to-edge repair (TEER) compared to medical therapy alone in patients with severe TR.
- The study included 572 patients who were split into TEER and control groups, examining how changes in end-organ function correlate with hospitalizations for heart failure (HF) and mortality over 12 months.
- Results showed that while TEER did not significantly differ from medical therapy alone in overall end-organ function improvements, successful TEER did lead to enhanced function in specific patient subgroups, indicating potential benefits in targeted treatment.
An international, expert-based, Delphi consensus document on controversial issues in the management of abdominal aortic aneurysms.
J Vasc Surg
August 2024
Vascular Surgery, University of Bologna - DIMEC, Bologna, Italy.
Article Synopsis
- The Delphi consensus aimed to clarify management practices for abdominal aortic aneurysms (AAAs) due to conflicting data in previous literature.
- A group of 44 experts anonymously discussed six key topics over three rounds, achieving a 100% response rate.
- Key findings included the agreement on minimum case volume for AAA repairs, the effectiveness of screening programs, lifelong surveillance after repair, and the consideration of screening for women smokers at 65, but no consensus on certain repair thresholds or thrombosis prevention was reached.
Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis.
Neurology
September 2024
From the Faculty of Medicine and Health (M.J.L., D.M.L., B.C.P.L., J.D.C., P.S.S.), and Centre for Healthy Brain Aging (CHeBA) (M.J.L., D.M.L., B.C.P.L., J.D.C., P.S.S.), Discipline of Psychiatry & Mental Health, School of Clinical Medicine, University of New South Wales, Sydney; School of Psychology and Public Health (B.C.P.L.), La Trobe University, Melbourne; The George Institute for Global Health (A.E.S., R.P.), Barangaroo; School of Biomedical Sciences (R.P.), University of New South Wales, Sydney, Australia; School of Public Health (R.P.), Imperial College London, United Kingdom; School of Population Health (A.E.S.), University of New South Wales, Sydney, Australia; Neuropsychiatric Epidemiology Unit (T.R.-S., J.N., I.S.), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Centre for Ageing and Health (AGECAP) at the University of Gothenburg; Aging Research Center (T.R.-S.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Region Västra Götaland (J.N., I.S.), Sahlgrenska University Hospital, Psychiatry, Cognition and Old Age Psychiatry Clinic, Gothenburg, Sweden; Section Genomics of Neurodegenerative Diseases and Aging (J.N.), Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands; Institute of Social Medicine (S.G.R.-H., S.R., A.P.), Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Germany; School of Psychology (S.R.), Massey University, Albany Campus, Auckland, New Zealand; Global Brain Health Institute (GBHI) (S.R.), Trinity College Dublin, Ireland; Department of Medicine and Psychiatry (A.L., C.D.-l-C.), Universidad de Zaragoza; Instituto de Investigación Sanitaria Aragón (IIS Aragón) (A.L., C.D.-l-C., E.L.), Zaragoza; CIBERSAM (A.L., C.D.-l-C., E.L.), Madrid, Spain; Department of Preventive Medicine and Public Health (E.L.), Universidad de Zaragoza, Spain; Department of Neurology (R.B.L., M.J.K., C.A.D.), and Department of Epidemiology and Population Health (R.B.L., C.A.D.), Albert Einstein College of Medicine, Bronx, NY; Department of Neuropsychiatry (K.W.K., J.W.H.), Seoul National University Bundang Hospital, Seongnam; Department of Psychiatry (K.W.K., J.W.H.), Seoul National University College of Medicine; Department of Brain and Cognitive Sciences (K.W.K.), Seoul National University College of Natural Sciences; Workplace Mental Health Institute (D.J.O.), Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Golgi Cenci Foundation (E.R., A.D., M.R.), Abbiategrasso, Milan; Department of Brain and Behavioural Sciences (E.R.), University of Pavia, Italy; 1st Department of Neurology (N.S.), Aiginition Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (N.S.), Columbia University, New York, NY; School of Health Sciences and Education (M.Y.), Department of Nutrition and Dietetics, Harokopio University; Department of Neurology (T.D.), University Hospital of Larissa; Faculty of Medicine (T.D.), School of Health Sciences, University of Thessaly, Larissa, Greece; Department of Psychiatry (H.C.H.), Indiana University School of Medicine; Indiana Alzheimer Disease Research Center (H.C.H., S.G.), Indiana Alzheimer Disease Research Center; Department of Biostatistics and Health Data Science (S.G.), Indiana University School of Medicine, Indianapolis; Institut for Neurosciences of Montpellier INM (I.C., K.R.), University Montpellier, INSERM; Institut du Cerveau Trocadéro (K.R.), Paris, France; School of Psychology (K.J.A.), and Ageing Futures Institute (K.J.A.), University of New South Wales; Neuroscience Research Australia (K.J.A.), Sydney; National Centre for Epidemiology and Population Health (N.C.), Australian National University, Canberra, Australia; Department of Geriatric Psychiatry (S.X., L.Y., W.L.), Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; Alzheimer's Disease and Related Disorders Center (S.X., L.Y., W.L.), Shanghai Jiao Tong University, China; Inserm U1094 (M.G., P.-M.P., V.A.), IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT-Epidemiology of Chronic Diseases in Tropical Zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, France; Laboratory of Chronic and Neurological Diseases Epidemiology (LEMACEN) (M.G.), Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin; Department of Cardiology (V.A.), Dupuytren 2 University Hospital, Limoges, France; School of Medicine (M.N.H.), University of California, San Francisco; Robert N. Butler Columbia Aging Center (A.A.), Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; Departamento de Psiquiatria (M.S.), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Brazil; and Neuropsychiatric Institute (P.S.S.), Prince of Wales Hospital, Sydney, Australia.
Article Synopsis
- Previous studies suggest that using antihypertensive medication in older adults may lower the overall risk of dementia, but the effects on different types of dementia, particularly Alzheimer’s disease (AD), are still uncertain.
- This research analyzed data from over 31,000 participants across multiple countries, focusing on how history of hypertension and blood pressure levels impact the risk of developing AD and non-AD types of dementia.
- The findings indicated that untreated hypertension significantly increases the risk of developing AD and non-AD dementia compared to healthy individuals, while treated hypertension showed a similar risk for non-AD but not a significant difference between treated and untreated groups.
Patient profiled data for treatment decision-making: valuable as an add-on to hepatitis C clinical guidelines?
BMC Med Inform Decis Mak
August 2024
Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Background And Aims: Systematic reviews and medical guidelines are widely used in clinical practice. However, these are often not up-to-date and focussed on the average patient. We therefore aimed to evaluate a guideline add-on, TherapySelector (TS), which is based on monthly updated data of all available high-quality studies, classified in specific patient profiles.
View Article and Find Full Text PDFComplete sequencing of ape genomes.
bioRxiv
October 2024
Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Article Synopsis
- The study presents detailed genomes of six ape species, achieving high accuracy and complete sequencing of all their chromosomes.
- It addresses complex genomic regions, leading to enhanced understanding of evolutionary relationships among these species.
- The findings will serve as a crucial resource for future research on human evolution and our closest ape relatives.
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Lancet
August 2024
Novartis Pharma, Basel, Switzerland. Electronic address:
Background: Sjögren's disease is a chronic autoimmune disease with an unmet need for targeted therapies. The aim of the TWINSS study is to evaluate the safety and efficacy of iscalimab, a monoclonal antibody against CD40, in patients with active Sjögren's disease.
Methods: This randomised, double-blind, placebo-controlled, phase 2b study, conducted at 71 sites in 23 countries, enrolled patients aged 18 years or older fulfilling the American College of Rheumatology/European Alliance of Associations for Rheumatology (EULAR) 2016 criteria.
The E3 ubiquitin ligase Herc1 modulates the response to nucleoside analogs in acute myeloid leukemia.
Blood Adv
October 2024
Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Canada.
Article Synopsis
- Scientists have been using special medicines called nucleoside analogs, like cytarabine, to treat a type of blood cancer called acute myeloid leukemia (AML) for many years.
- However, some patients don’t respond well to these medicines because their cancer cells become resistant to treatment.
- Researchers discovered that a protein named HERC1 affects how well these medicines work, and targeting HERC1 could help improve AML treatments in the future.
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Mult Scler
August 2024
CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
Background: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking.
Objectives: To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting MS.
Methods: Patients with relapsing-remitting MS treated with cladribine, fingolimod, natalizumab, ocrelizumab or alemtuzumab were identified in the global MSBase cohort and two additional UK centres.
Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells.
NPJ Precis Oncol
July 2024
Department of General Surgery, Molecular Oncology and Immunotherapy, University Medicine Rostock, Rostock, Germany.
Two hypermutated colon cancer cases with patient-derived cell lines, peripheral and tumor-infiltrating T cells available were selected for detailed investigation of immunological response.T cells co-cultured with autologous tumor cells showed only low levels of pro-inflammatory cytokines and failed at tumor recognition. Similarly, treatment of co-cultures with immune checkpoint inhibitors (ICI) did not boost antitumor immune responses.
View Article and Find Full Text PDFComparing the haemodynamic effects of high- and low-dose opioid anaesthesia: a secondary analysis of a randomised controlled trial.
J Clin Monit Comput
December 2024
Department of Anaesthesiology, University Medical Centre Groningen, Groningen, Netherlands.
Unlabelled: Post-induction hypotension (MAP < 65 mmHg) occurs frequently and is usually caused by the cardiovascular adverse effects of the anaesthetic induction drugs used. We hypothesize that a clinically significant difference in the incidence and severity of hypotension will be found when different doses of propofol and remifentanil are used for induction of anaesthesia.
Methods: This is a secondary analysis of a randomised controlled trial wherein four groups (A-D) of patients received one out of four different combinations of propofol and remifentanil, titrated to a predicted equipotency in probability of tolerance to laryngoscopy (PTOL) according to the Bouillon interaction model.
Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis.
Eur J Neurol
October 2024
Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.
Article Synopsis
- Multiple sclerosis (MS) is influenced by genetic and environmental factors, with viruses like Epstein-Barr and potentially rubella virus (RV) being linked to increased risk.
- This study analyzed the immune response to RV in a Swedish cohort, comparing serological responses in individuals before MS onset, both vaccinated and unvaccinated against RV.
- Results showed that unvaccinated individuals with RV seropositivity had a significantly higher risk of developing MS, suggesting a potential role of rubella virus in MS development, possibly through mechanisms like molecular mimicry with nervous system components.
Open Access Data and Deep Learning for Cardiac Device Identification on Standard DICOM and Smartphone-based Chest Radiographs.
Radiol Artif Intell
September 2024
From the Department of Radiology (F.B., L.H., S.M.N.), Department of Anesthesiology, Division of Operative Intensive Care Medicine (F.B.), Department of Cardiology (P.S.), and Department of Rheumatology (K.B.B., D.P., A.Z.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, 12203 Berlin, Germany; Department of Radiology and Nuclear Medicine, German Heart Center, Technical University of Munich, Munich, Germany (K.K.B.); Department of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany (F.B., K.K.B., M.R.M., L.C.A.); Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Departments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Mass (H.J.W.L.A.); and Department of Radiology and Nuclear Medicine, CARIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.).
Purpose To develop and evaluate a publicly available deep learning model for segmenting and classifying cardiac implantable electronic devices (CIEDs) on Digital Imaging and Communications in Medicine (DICOM) and smartphone-based chest radiographs. Materials and Methods This institutional review board-approved retrospective study included patients with implantable pacemakers, cardioverter defibrillators, cardiac resynchronization therapy devices, and cardiac monitors who underwent chest radiography between January 2012 and January 2022. A U-Net model with a ResNet-50 backbone was created to classify CIEDs on DICOM and smartphone images.
View Article and Find Full Text PDFClinical outcomes and predictors of transapical transcatheter mitral valve replacement: the Tendyne Expanded Clinical Study.
EuroIntervention
July 2024
Department of Cardiovascular & Thoracic Surgery, West Virginia University, Morgantown, WV, USA.
Background: Transcatheter mitral valve replacement (TMVR) is a therapeutic option for patients with severe mitral regurgitation (MR) who are ineligible for conventional surgery. There are limited data on the outcomes of large patient cohorts treated with TMVR.
Aims: This study aimed to investigate the outcomes and predictors of mortality for patients treated with transapical TMVR.
Structure of Polaronic Centers in Proton-Intercalated WO Scheelite-Type Tungstates.
Materials (Basel)
June 2024
Institute of Solid State Physics, University of Latvia, 8 Kengaraga Street, LV-1063 Riga, Latvia.
The studies of polaronic centers in a homologous series of scheelite-type compounds WO ( = Ca, Sr, Ba) were performed using the W L-edge and Sr K-edge X-ray absorption spectroscopy combined with the reverse Monte Carlo simulations, X-ray photoelectron spectroscopy (XPS), and first-principles calculations. Protonated scheelites HWO were produced using acid electrolytes in a one-step route at ambient conditions. The underlying mechanism behind this phenomenon can be ascribed to the intercalation of H into the crystal structure of tungstate, effectively resulting in the reduction of W to W, i.
View Article and Find Full Text PDFPlasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease.
Alzheimers Dement
August 2024
Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.
Introduction: Blood-based biomarkers are a cost-effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation-immunoassay (IP-IA) as a test for predicting cognitive decline.
Methods: We measured levels of amyloid beta (Aβ)X-40 and AβX-42 in immunoprecipitated eluates from the DELCODE cohort.
Antithrombotic Therapy in Patients With Infective Endocarditis: A Systematic Review and Meta-Analysis.
JACC Adv
February 2024
Department of Cardiothoracic Surgery, Friedrich-Schiller-University, Jena, Germany.
Background: Antithrombotic therapy (ATT) in patients with infective endocarditis (IE) is challenging.
Objectives: The authors evaluated the impact of anticoagulant and antiplatelet therapy on clinical endpoints in IE patients.
Methods: We performed a systematic review and meta-analysis comparing IE patients with prior and/or ongoing use of ATT vs those without any ATT during IE course.
Optimization of window settings for coronary arteries assessment using spectral CT-derived virtual monoenergetic imaging.
Radiol Med
July 2024
Division of Experimental Imaging, Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.
Purpose: To determine the optimal window setting for virtual monoenergetic images (VMI) reconstructed from dual-layer spectral coronary computed tomography angiography (DE-CCTA) datasets.
Material And Methods: 50 patients (30 males; mean age 61.1 ± 12.
Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes.
Diabetes Care
August 2024
Mount Sinai South Nassau, Oceanside, NY.
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programs are being increasingly emphasized. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody-positive (IAb+) children and adults who are at risk for (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in nonspecialized settings.
View Article and Find Full Text PDFRequired knowledge for guideline panel members to develop healthcare related testing recommendations: a developmental study.
J Clin Epidemiol
September 2024
Department Epidemiology and Data Science, Amsterdam UMC/University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Public Health Research Institute, Methodology Program, Amsterdam, The Netherlands.
Objectives: To define the minimum knowledge required for guideline panel members (healthcare professionals and consumers) involved in developing recommendations about healthcare related testing.
Study Design And Setting: A developmental study with a multistaged approach. We derived a first set of knowledge components from literature and subsequently performed semistructured interviews with 9 experts.
Intravascular Lithotripsy for Treatment of Severely Calcified Common Femoral Artery Disease: Results From the Disrupt PAD III Observational Study.
J Endovasc Ther
June 2024
Lifespan Cardiovascular Institute, The Miriam Hospital, Providence, RI, USA.
Background: Surgical endarterectomy is currently considered the front-line therapy for the treatment of calcified lesions in the common femoral artery (CFA). Endovascular interventions have evolved, and their use is increasing in frequency. Intravascular lithotripsy (IVL) has shown promising safety and effectiveness in calcified CFA lesions in a small pilot study, but "real-world" evidence from a larger cohort is lacking.
View Article and Find Full Text PDFEndovascular therapy of isolated posterior cerebral artery occlusion stroke with and without general anesthesia.
J Neurointerv Surg
August 2024
Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
Article Synopsis
- The study investigates the effectiveness of two anesthesia methods—general anesthesia (GA) and conscious sedation (non-GA)—for patients undergoing endovascular treatment for isolated posterior cerebral artery (PCA) occlusion stroke.
- Researchers analyzed data from the PLATO study focusing on patient outcomes such as the modified Rankin Scale scores after 90 days, as well as successful reperfusion rates and safety measures like intracranial hemorrhage.
- Results show that while both anesthesia methods had similar functional outcomes and safety profiles, GA was associated with significantly higher rates of successful reperfusion during treatment.
Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Neurology
June 2024
From the Department of Laboratory Medicine (K.B., E.R.B., E.A.J.W., C.E.T.) and Alzheimer Center Amsterdam (A.A.J.M.U., A.W.L.), Amsterdam UMC, the Netherlands; Department of Quality and Health Technology (M.C.G.), University of Stavanger; The Norwegian Centre for Movement Disorders (M.C.G.) and the Centre for Age-Related Medicine (M.C.G., N.J.A., D.A.), Stavanger University Hospital, Norway; Department of Psychiatry and Neurochemistry (N.J.A., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Old Age Psychiatry (N.J.A., D.A.), King's College London, United Kingdom; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; UK Dementia Research Institute at UCL (H.Z.), London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), Hong Kong, China; Wisconsin Alzheimer's Disease Research Center (H.Z.), University of Wisconsin School of Medicine and Public Health, Madison; Neurology Unit (A.P.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Medicine and Aging Sciences (L.B.), University G. d'Annunzio of Chieti-Pescara, Chieti, Italy; Department of Neurology (B.M.), University Medical Center Göttingen; Paracelsus-Elena-Klinik (B.M., S.S.), Germany; Department of Neurosciences (R.V., K.P.), KU Leuven, Belgium; Department of Neurology and Medical Faculty (M.G.K.), University Medical Center Ljubljana, Slovenia; Department of Neurobiology (M.G.K.), Karolinska Institutet, Huddinge, Sweden; Université de Paris Cité (C.P.), Centre de Neurologie Cognitive, Paris; Laboratory of Biochemistry and Molecular Biology (O.B.), University Hospital of Strasbourg; University of Strasbourg and CNRS (O.B., B.C.); Memory Resource and Research Centre (B.C.), University Hospital of Strasbourg, France; Department of Neurology (E.A.J.W.), Multiple Sclerosis Center; Research Center for Clinical Neuroimmunology and Neuroscience Basel (E.A.J.W.); and Departments of Biomedicine and Clinical Research (E.A.J.W.), University Hospital Basel and University of Basel, Switzerland.
Background And Objectives: Plasma β-amyloid-1-42/1-40 (Aβ42/40), phosphorylated-tau (P-tau), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) have been widely examined in Alzheimer disease (AD), but little is known about their reflection of copathologies, clinical importance, and predictive value in dementia with Lewy bodies (DLB). We aimed to evaluate associations of these biomarkers with CSF amyloid, cognition, and core features in DLB.
Methods: This cross-sectional multicenter cohort study with prospective component included individuals with DLB, AD, and healthy controls (HCs), recruited from 2002 to 2020 with an annual follow-up of up to 5 years, from the European-Dementia With Lewy Bodies consortium.
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
N Engl J Med
November 2024
From the Departments of Medical Oncology (C.U.B., M.W.L., L.L.H., J.M.L., S.M.P., J.B.A.G.H., K.A.T.N., J.V.T., S.W., A.M.-E., I.L.M.R.), Pathology (B.A.W.), Biometrics (M.L.-Y., A.T.A., L.G.G.-O.), Surgical Oncology (W.J.H., A.M.J.K., A.C.J.A.), Head and Neck Surgery (W.M.C.K., C.L.Z.), Radiology (B.A.S.), and Molecular Oncology and Immunology (J.B.A.G.H.), Netherlands Cancer Institute, and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam (A.J.M.E.), Amsterdam, the Departments of Medical Oncology (C.U.B., J.B.A.G.H., F.M.S., E.K.) and Otorhinolaryngology Head and Neck Surgery (C.L.Z.), Leiden University Medical Center, Leiden, the Departments of Medical Oncology (K.A.T.N., R.C.S., A.A.M.V.), Surgical Oncology (D.J.G., R.C.S.), and Radiology and Nuclear Medicine (A.A.M.V.), Erasmus Medical Center, Rotterdam, the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht (S.B.V., K.P.M.S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (R.R.), the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.), the Department of Medical Oncology, Medisch Spectrum Twente, Enschede (D.P.), the Department of Medical Oncology, Maxima Medical Center, Veldhoven (G.V.), the Department of Medical Oncology, Maastricht University Medical Center, GROW School for Oncology and Developmental Biology, Maastricht (M.J.B.A.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.B.), the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen (G.A.P.H.), and Isala Oncology Center, Isala Hospital, Zwolle (J.-W.B.G.) - all in the Netherlands; the Department of Hematology and Medical Oncology, University Clinic Regensburg, Regensburg, Germany (C.U.B.); Melanoma Institute Australia (R.A.S., A.M.M., R.P.M.S., N.G.M., M.G., S.N.L., A.S., T.E.P., K.F.S., R.V.R., S.C., J.S., M.A.R., A.C.J.A., M.S.C., G.V.L.), the Faculty of Medicine and Health (R.A.S., A.M.M., R.P.M.S., N.G.M., S.N.L., A.S., T.E.P., K.F.S., S.C., J.S., M.A.R., A.C.J.A., G.V.L.), and Charles Perkins Centre (R.A.S., G.V.L.), University of Sydney, the Departments of Tissue Pathology and Diagnostic Oncology (R.A.S., R.V.R.) and Melanoma and Surgical Oncology (R.P.M.S., T.E.P., K.F.S., S.C., J.S., M.A.R., A.C.J.A.), Royal Prince Alfred Hospital, NSW Health Pathology (R.A.S., R.V.R.), the Departments of Medical Oncology (A.M.M., G.V.L.) and Breast and Melanoma Surgery (A.S.), Royal North Shore and Mater Hospitals, and the Department of Radiology, Mater Hospital (R.K.), Sydney, Royal Prince Alfred Hospital, Institute of Academic Surgery, Camperdown, NSW (A.C.J.A.), the Division of Cancer Surgery, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC (D.E.G.), the Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC (L.S., S.S.), Lake Macquarie Oncology, Lake Macquarie Private Hospital, the Department of Medical Oncology, Calvary Mater Hospital, and the Department of Medicine, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (A.W.), the Department of Medical Oncology, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), the Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA (M.K.), the Department of Medical Oncology, Alfred Health, Melbourne, and the Department of Medicine, School of Translational Medicine, Monash University, Melbourne, VIC (M.C.A.), and the Department of Medical Oncology, Westmead Hospital and Blacktown, Sydney (M.S.C.) - all in Australia; the Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (J.B.A.G.H.); the Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (J.P., P.R.); the Department of Medical Oncology, Centre Léon Bérard, Lyon (M.A.-A.), Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP) Dermato-Oncology and Clinical Investigation Center, Cancer Institute AP-HP, Nord Paris Cité, INSERM Unité 976, Saint Louis Hospital, Paris (C.L.), and the Department of Medical Oncology, Gustave Roussy and Paris-Saclay University, Villejuif (C.R.) - all in France; the Department of Surgical Oncology, Angeles Clinic and Research Institute, Los Angeles (M.B.F.); and the Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy (P.A.A.).
Article Synopsis
- In a study comparing neoadjuvant (before surgery) and adjuvant (after surgery) immunotherapy for stage III melanoma, neoadjuvant treatment showed greater effectiveness.
- The trial involved random assignment of 423 patients to receive either two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery, or surgery followed by 12 cycles of adjuvant nivolumab.
- Results indicated a significantly higher 12-month event-free survival rate in the neoadjuvant group (83.7%) compared to the adjuvant group (57.2%), with neoadjuvant therapy leading to better patient outcomes and more major pathological responses despite a higher incidence of severe adverse events.